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Abstract: Background: Lung cancer is typically diagnosed in an advanced phase of its natural history.
Explanatory models based on epidemiological and clinical variables provide an approximation of
patient survival less than one year using information extracted from the case history only, whereas
models involving therapeutic variables must confirm that any treatment applied is worse than surgery
in survival terms. Models for classifying less than one year survival for patients diagnosed with lung
cancer which are able to identify risk factors and quantify their effect for prognosis are analyzed.
Method: Two stepwise binary logistic regression models, based on a retrospective study of 521 cases
of patients diagnosed with lung cancer in the Interventional Pneumology Unit at the Hospital “Virgen
de las Nieves”, Granada, Spain. Results: The first model included variables age, history of pulmonary
neoplasm, tumor location, dyspnea, dysphonia, and chest pain. The independent risk factors age
greater than 70 years, a peripheral location, dyspnea and dysphonia were significant. For the second
model, treatments were also significant. Conclusions: Age, history of pulmonary neoplasm, tumor
location, dyspnea, dysphonia, and chest pain are predictors for survival in patients diagnosed with
lung cancer at the time of diagnosis. The treatment applied is significant for classifying less than
one year survival time which confirms that any treatment is markedly inferior to surgery in terms of
survival. This allows to consider applications of more or less aggressive treatments, anticipation of
palliative cares or comfort measures, inclusion in clinical trials, etc.
Keywords: epidemiological risk factors; logistic regression; lung cancer; short-term survival; treatments
1. Introduction
Lung cancer is the most common cause of neoplasm-related death in both men and
women, causing around 1.3 million deaths per year worldwide [1–3]. Lung cancer patients
experience a wide range of symptoms depending, amongst other factors, on the anatomical
structures affected, with the most common being dyspnea, cough, hemoptysis, chest pain,
constitutional symptoms, and dysphonia [4,5]. Dyspnea is a very common symptom in
advanced lung cancer, being present in 65% of cases at some stage of the disease and
having a very marked impact on quality of life [6,7]. Cough, which tends to be caused
by intrinsic or extrinsic (adenopathies) obstruction of the trachea and proximal bronchi,
is also a common and annoying symptom for lung cancer patients and is often the first
symptom to appear [8]. Hemoptysis is present in 7–10% of lung cancer patients and is
the cause of death in 3% of cases, being more common in patients with central lesions of
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the airways than in those with peripheral lesions of the pulmonary parenchyma [9,10].
Chest pain is the most common symptom of lung cancer, being present in approximately
25% of cases at diagnosis and increasing in prevalence as the disease progresses [11].
Constitutional symptoms, including the presence of asthenia, anorexia, and weight loss,
generally present in advanced stages of lung cancer and are an important predictor of
mortality [12,13]. Dysphonia appears in lung cancer as a result of involvement of the
recurrent laryngeal nerve due to metastatic invasion of the mediastinum, mainly the one
located in the upper right paratracheal region or in the aortopulmonary window, and
generally implies advanced or non-resectable disease [14]. The main treatment options for
lung cancer are surgery, radiotherapy, and chemotherapy, either alone or in combination,
depending on the stage and histological subtype of the cancer and the clinical situation
and general condition of the patient. In advanced stages, or in patients with marked
clinical deterioration not susceptible to surgical treatment or chemo- or radiotherapy,
palliative care is considered in order to treat the symptoms caused by the cancer and its
progression [15–17]. The reason for classifying cancer into different groups or stages arises
due to the fact that survival is higher in patients in whom the disease is localized than
in those in whom the disease can be considered to be advanced. This division of lung
cancer into stages helps with treatment planning, gives an idea of the prognosis and allow
treatment outcomes to be evaluated [18]. Thus, in general terms, early stage non-small cell
lung cancer (stage I and II) is considered to be a good candidate for surgical treatment,
with a higher survival rate than for patients in advanced stages (III and IV). The latter
benefit from chemotherapy and/or radiotherapy rather than being candidates for surgical
treatment, except in the case of stage IIIA, where surgery with prior neoadjuvant therapy
can be considered [19–22]. Non-small cell lung cancer (NSCLC) corresponds to 85% of lung
cancers and, unfortunately, up to 80% of cases are diagnosed in advanced stages requiring
systemic therapy. The treatment of these patients has made significant progress in recent
decades with the emergence of specific mutations targeting therapies (known as targeted
therapies) and more recently with immunotherapy, being an increasingly common therapy.
Lung cancer is typically diagnosed in an advanced phase of its natural history, thus
resulting in a five-year mortality from diagnosis of 85–90%, with the one-year survival for
small-cell carcinoma being markedly lower [23]. In addition, around 80% of patients are
inoperable or non-resectable at diagnosis. Consequently, when diagnosed, most cases are
not susceptible to curative surgical treatment, with the remaining therapeutic alternatives
being mainly chemotherapy, radiotherapy, palliative care, or a combination thereof [24].
Explanatory models based on epidemiological and clinical variables could provide a first
approximation of patient survival using information extracted from the case history only,
or obtained from non-invasive complementary tests, whereas models involving therapeutic
variables must confirm that any treatment applied is worse than surgery in survival terms.
This study has the purpose to identify risk factors and quantify their effect for prog-
nosis for classifying survivals of less than or more than one year for patients diagnosed
with non-small cell lung cancer, based on, by means of non-invasive procedures, clini-
cal/epidemiological characteristics at diagnosis and with respect to the treatments received.
2. Materials and Methods
2.1. Participants
The sample comprised 521 patients diagnosed with non-small cell lung cancer at the
Diagnostic Techniques Unit of the Pneumology Service at the Hospital Virgen de las Nieves
between 1 January 2011 and 31 December 2016. The mean age of the subjects was 65.2 years
(SD = 10.44), 22.3% of them were female, and 38.2% presented survival times of longer than
one year.
2.2. The Procedure
A retrospective study comprising all patients was carried out. These patients came
from the health region for the Universitary Hospital Virgen de las Nieves, which comprises
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the northern part of Granada and its province, as well as the provinces of Jaén and Almería.
Data were obtained from the computerized medical records of each patient and from the
provincial tumor registry for Granada. Epidemiological variables, such as age, sex, smoking
history and prior neoplasms, and clinical variables, such as the presence of dyspnea, cough,
chest pain, hemoptysis, constitutional symptoms, and dysphonia, diagnostic variables
related to the way in which the diagnosis of lung cancer was reached in each patient, such
as the application of various bronchoscopy techniques (endobronchial biopsy, cytological
brushing, or blind puncture), echo-bronchoscopy-guided puncture, ultrasound or CT and
PET-CT as an extension and staging study, amongst others, and therapeutic variables,
which included the initial treatment administered or applied to the patient upon diagnosis,
mainly surgery, chemotherapy, radiotherapy, palliative care, or a combination thereof, were
collected. Finally, survival data were collected by obtaining the exact date of death from
the electronic records of the regional healthcare system in Andalusia.
2.3. Statistical Methods
Logistic regression is one of the statistical tools with the best capacity for data analysis
in clinical and epidemiological research; hence, its wide use [25]. According to [26,27] it is
a statistical tool for multivariate analysis, which provides information of two types. Firstly,
logistic regression provides information of which explanatory variables are risk factors
because they involve level changes in the dependent variable. Secondly, this model also
provides predictive information because it calculates probabilities of an individual classify
in a level response of the dependent variable in relation to the values of the explanatory
variables. This allows to build diagnostic tools that once validated can be useful to classify
individuals in relation to their response to a pathology according to the risk factors included
in the model.
The logit model allows another type of analysis, by means of Odds-Ratio. They are
the exponentials of the parameters estimated for each of the risk factors within the model.
They provides information about how much is multiplied the advantage of answering a
value of the dependent variable versus to another when comparing two categories of the
explanatory variable (if it is categorical) or increasing one unit (if it is quantitative).
A binary-response logistic regression model (logit) was used [25–27]. Two models were
fitted for the response variable that informs regarding the survival time less than or greater
than one year: a first model considering clinical/epidemiological data as explanatory
variables and a secondary model considering the therapeutic variables as regressors. These
models were used to determine which variables caused these patients to have a survival
of less than one year. A model containing the effects of the factors, with no interaction
between them, was considered to best fit the data. This model was fitted in a stepwise way
starting from a constant model, using forward selection to determine whether a variable
enters, and backward selection to determine whether it exits, in each step. The goodness-of-
fit was compared using the likelihood ratio test, the Hosmer–Lemeshow test and Pearson’s
chi-squared test. The statistical significance of the parameters for the variables that enter
into each model was evaluated using Wald’s test and the prognosis ratios for each level
with respect to the adjacent level were obtained, depending on the possible changes in the
explanatory variables considered. Statistical analyses were performed using the program
SPSS 19.0.
2.4. Ethical Considerations
The study was carried out in accordance with the 1975 Declaration of Helsinki [28]
and was approved by the Clinical Research Ethics Committee at the Andalusian Health
Service (LUNG CA SURV 2180-N-20). The data were processed in accordance with the
provisions of Act 15/1999, of 13 December, on the Protection of Personal Data.
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3. Results
3.1. Description of the Sample
The survival times after a diagnosis of cancer were classified into less than or more
than one year. The descriptive analysis of the epidemiological, clinical and therapeutic
variables considered, and the survival times, are shown in Table 1.
Table 1. Description of variables.
Response Variable Level % (n)
SUR = Survival (n = 521) (0) Less than one year 61.8 (322)(1) More than one year 38.2 (199)
Epidemiological Variables Level % (n)
S = Sex (n = 521) (0) Male 77.7 (405)(1) Female 22.3 (116)
A = Age (n = 521)
(0) <40 years 1.3 (7)
(1) 41–50 years 6.7 (35)
(2) 51–60 years 24.0 (125)
(3) 61–70 years 34.9 (182)
(4) >70 years 33.0 (172)
SMO = Current or former smoker? (n = 521) (0) Never 12.5 (65)(1) Smoker or ex-smoker 87.5 (456)
PACK = Packs per year (n = 521)
(0) <15 17.7 (92)
(1) 15–30 15.4 (80)
(2) 30–50 31.1 (162)
(3) >50 35.9 (187)
NOPULNEO = History of NON-pulmonary
neoplasm (n = 521)
(0) NO 75.8 (395)
(1) YES 24.2 (126)
PULNEO = History of pulmonary neoplasm
(n = 521)
(0) NO 97.3 (507)
(1) YES 2.7 (14)
Clinical Variables Level % (n)
CP = Chest pain (n = 521) (0) NO 64.9 (338)
(1) YES 35.1 (183)
DYSN = Dyspnea (n = 521) (0) NO 63.1 (329)
(1) YES 36.9 (192)
DYSP = Dysphonia (n = 521) (0) NO 93.1 (485)
(1) YES 6.9 (36)
HAEM = Haemoptysis (n = 521) (0) NO 79.3 (413)
(1) YES 20.7 (108)
COU = Cough (n = 521) (0) NO 54.5 (284)
(1) YES 45.5 (237)
CS = Constitutional symptoms (n = 521) (0) NO 66.2 (345)
(1) YES 33.8 (176)
LOC = Location (n = 521)
(0) Central 28.6 (149)
(1) Peripheral 8.8 (46)
(2) Central and peripheral 62.6 (326)
Therapeutic Variables Level % (n)
TT = Treatment (n = 521)
(0) Surgery 5.2 (27)
(1) Conventional chemotherapy 19.4 (101)
(2) Chemotherapy + Radiotherapy 28.6 (149)
(3) Palliative care (PC) 13.6 (71)
(4) Chemotherapy + PC 5.0 (26)
(5) Radiotherapy + PC 4.2 (22)
(6) Other treatments 24.0 (125)
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3.2. Explanatory Model with Clinical/Epidemiological Variables
The estimated model for the survival time (SUR) includes the explanatory epidemio-
logical variables age (A) and history of pulmonary neoplasm (PULNEO), as well as the
clinical variables location (LOC), dyspnea (DYSN), dysphonia (DYSP), and chest pain (CP),

















i = 1,2,3,4,5; k = 1,2,3; j,l,m,n = 1,2 (2)
(A)1 = (PULNEO)1 = (LOC)1 = (DYSN)1 = (DYSP)1 = (CP)1 = 0 (3)
The parameters estimated for each explanatory variable in the binary logistic regres-
sion model for survival can be found in Table 2 below.
Table 2. Logit model for survival (clinical and epidemiological variables).
Predictor B DT Wald p-Value Odd
CI for 95% Odds
Lower Upper
Constant 1.291 0.879 2.157 0.142 3.637
(A)2 −0.793 0.919 0.744 0.388 0.453 0.075 2.741
(A)3 −1.401 0.873 2.575 0.109 0.246 0.045 1.364
(A)4 −1.632 0.867 3.538 0.060 0.196 0.036 1.071
(A)5 −1.967 0.870 5.112 0.024 0.140 0.025 0.770
(PULNEO)2 1.065 0.587 3.293 0.070 2.901 0.918 9.166
(LOC)2 0.920 0.356 6.670 0.010 2.509 1.248 5.044
(LOC)3 0.082 0.215 0.144 0.704 1.085 0.712 1.655
(DYSN)2 −0.463 0.200 5.328 0.021 0.630 0.425 0.933
(DYSP)2 −0.928 0.425 7.766 0.029 0.395 0.172 0.909
(CP)2 −0.342 0.202 2.872 0.090 0.710 0.478 1.055
Note: The reference category for the response variable is less than one year. For the explanatory variable
age is: <40 years, for the history of pulmonary neoplasm it is: NO, for location it is central, for dyspnea it is:
NO, for dysphonia it is: NO and for chest pain it is: NO. A = Age; B = coefficient; DT = Standard deviation;
DYSP = Dysphonia; DYSN = Dysnea; LOC = Location; PULNEO = History of pulmonary neoplasm.
In light of the results of the Wald test (see Table 2), the variables aged more than
70 years (p = 0.024), a peripheral location (p = 0.010), and the patient presenting dyspnea
(p = 0.021) and dysphonia (p = 0.029) are significant at a population-based level. Conse-
quently, the prognosis change ratio for the levels considered (survival greater than vs. less
than one year) was analysed for the variables found to be significant in the model. For the
age variable, it should be noted that the prognosis ratio for a survival of less than one year
was sevenfold higher for patients aged more than 70 years than for those aged less than
40 years (odds ratio (OR) = 0.140; 95% credible interval [CI]: 0.025–0.770). As regards tumor
location, the advantage of surviving for more than one year was almost threefold higher in
patients with a peripheral tumor location than in those with a tumor in the central region
(OR = 2.509; 95% CI: 1.248–5.044). In the case of patients with dyspnea and dysphonia, the
possibility of surviving for less than one year was almost twofold (OR = 0.630; 95% CI:
0.425–0.933) and almost threefold higher (OR = 0.395; 95% CI: 0.172–0.909), respectively,
than in patients not presenting these clinical symptoms.
3.3. Explanatory Model with Therapeutic Variables
The estimated model for the survival time (SUR) includes the therapeutic treatment
(TT) as explanatory variable and has the following form:
L̂i,j,k,l,m,n = B̂0 − B̂TT(TT)i (4)
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i = 1, 2, 3, 4, 5, 6, 7 (5)
(TT)1 = 0 (6)
The parameters estimated for each explanatory variable in the binary logistic regres-
sion model for survival can be found in Table 3 below.
Table 3. Logit model for survival (therapeutic variable).
Predictor B DT Wald p Odd
CI for 95% Odds
Lower Upper
Constant 1.253 0.463 7.324 0.007 3.500
(TT)2 −1.758 0.506 12.054 0.001 0.172 0.064 0.465
(TT)3 −1.320 0.491 7.224 0.007 0.267 0.102 0.699
(TT)4 −4.071 0.692 34.587 0.000 0.017 0.004 0.066
(TT)5 −4.472 1.120 15.942 0.000 0.011 0.001 0.103
(TT)6 −2.477 0.688 12.964 0.000 0.084 0.022 0.324
(TT)7 −1.397 0.496 7.919 0.005 0.247 0.093 0.654
Note: The reference category for the response variable is: less than one year. For the explanatory variable
treatment, the reference category is surgery. B = coefficient; DT = Standard deviation; TT = Treament.
Once again, in light of the results of the Wald test (see Table 3), all treatments consid-
ered were found to be significant at a population-based level. Consequently, the prognosis
change ratio for the levels considered (survival greater than vs. less than one year) was
analysed by comparing each of the treatments with surgery, which is the reference treat-
ment used in the model. In the case of conventional chemotherapy, the prognosis ratio
for survival of less than one year was sixfold higher (OR = 0.172; 95% CI: 0.0064–0.465)
with respect to surgery, whereas the combination chemotherapy/radiotherapy was almost
fourfold higher (OR = 0.267; 95% CI: 0.102–0.699). This ratio was 60-fold higher for pal-
liative care (OR = 0.017; 95% CI: 0.004–0.066), 90-fold higher in the case of chemotherapy
combined with palliative care (OR = 0.011; 95% CI: 0.001–0.103), and 11-fold higher in
the case of radiotherapy combined with palliative care (OR = 0.084; 95% CI: 0.022–0.324).
Finally, in the case of treatments other than those discussed above, this ratio for a prognosis
of survival for less than one year was fourfold higher (OR = 0.247; 95% CI: 0.093–0.654)
than for surgery.
4. Discussion
The aim of this study was to establish models for classifying survivals of less than or
more than one year for patients diagnosed with lung cancer, based on clinical/epidemiological
characteristics at diagnosis and with respect to the treatments received, as well as to identify
which of these variables were actually risk factors and to quantify their effect for prognosis.
With regard to the first objective and the clinical/epidemiological characteristics, a model
that provides a first approximation of patient survival based on data extracted only from the
case history or provided by non-invasive complementary tests was obtained. This model
included the epidemiological variables age and history of pulmonary neoplasm and the
clinical variables location, dyspnea, dysphonia, and chest pain as predictors for a survival
time of less than one year for patients diagnosed with lung cancer at the time of diagnosis.
Similarly, with regard to the treatment applied or administered, a model that includes
this treatment as a significant element for classifying a survival time of less than one year
has been obtained. With regard to the second objective, from a clinical/epidemiological
viewpoint, an age of more than 70 years, a central location and presenting dyspnea and
dysphonia were all found to be risk factors for a survival time of less than one year. Finally,
from a therapeutic viewpoint, it was found that treatment is a risk factor for prognosis of a
survival time of less than one year and that any treatment applied is worse than surgery in
survival terms.
This study provides models that classify patients of lung cancer in a level of survival
less or greater than one year based on modifiable risk factors associated to clinical variables
J. Clin. Med. 2021, 10, 519 7 of 9
as well as related to the treatment received. However, there are several inherent limitations.
First, from a clinical/epidemiological viewpoint, the model estimated for a survival-
based classification does not take into account other key variables for this purpose. For
example, the diagnosis and cytohistological staging of the neoplasm [28,29], or other
chronic comorbidities or conditions that may themselves decrease the survival time, such
as arrhythmias, ischemic heart disease, diabetes mellitus, and advanced chronic obstructive
pulmonary disease, amongst others [30]. For the therapeutic variables, changes to the
oncological treatment in patients with poor tolerance or evolution have not been taken
into consideration due to the difficulty in accessing this information. Second, although the
models are robust, possible interactions between the clinical/epidemiological risk factors
have also not been taken into consideration. Consequently, a study of these interactions
and the aforementioned variables would be of interest to develop and validate better
models for classifying survival times of less than one year [15,31–33]. Finally, the number
of patients susceptible to surgery, in other words diagnosed at an early stage, also needs
to be increased in order to be able to establish therapeutic groups. This group should be
as homogeneous as possible in terms of the number of individuals, although given the
unique characteristics of lung cancer in terms of the tendency to diagnose this disease in
an advanced stage referred to above. This objective will depend on an improvement in the
early diagnosis of lung cancer [34,35].
5. Conclusions
In the moment of diagnosis of lung cancer it becomes necessary a good prognosis of
the survival time based on the history of the patient. This fact jointly to the knowledge of
which is the best therapeutic treatment at this moment could help to mitigate the risk of
survival less than one year. Our findings of explanatory models based on epidemiological
and clinical variables provide a first approximation of patient survival using information
extracted from the case history only. This information allows to consider the application of
more or less aggressive treatments, anticipation of palliative cares or comfort measures,
inclusion in clinical trials or, in addition, to the important psychosocial and emotional im-
plications that are derived. On the other hand our model based on the different therapeutic
treatments confirms that that any treatment applied is worse than surgery in survival terms,
and it provides ratios between every couple of treatments for survival. Advancing the
fight against short-term survival for all lung cancer patients requires improvements of the
models and consequently an ongoing continuous research looking for models with more
risk factors involved and/or the interaction between all of them.
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